USFDA completes inspection at Biocon’s Vishakhapatnam facility

18 Sep 2017 Evaluate

Biocon’s Active Pharmaceutical Ingredients (API) manufacturing facility in Vishakhapatnam, Andhra Pradesh has completed the US Food and Drug Administration (USFDA) inspection and there were no observations (483) during the inspection. The inspection was carried out between September 11, 2017 to September 15, 2017. The successful audit of this facility reflects the company’s strong commitment to cGMP compliance at their manufacturing facilities. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

372.65 8.10 (2.22%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×